Cargando…

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea

SIMPLE SUMMARY: Recently, selpercatinib, a highly selective inhibitor of RET receptor tyrosine kinase, has been used for RET-altered thyroid cancer. However, real-world data of its effectiveness and safety in various clinical situations are lacking. We present four cases of patients with advanced th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baek, Han-Sang, Ha, Jeonghoon, Ha, Seunggyun, Bae, Ja Seong, Jung, Chan Kwon, Lim, Dong-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046919/ https://www.ncbi.nlm.nih.gov/pubmed/36975442 http://dx.doi.org/10.3390/curroncol30030229

Ejemplares similares

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
por: Sitbon, Marine, et al.
Publicado: (2022)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
por: Ragnarsson, Oskar, et al.
Publicado: (2022)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

A Case of Medullary Thyroid Carcinoma with de novo V804M RET Germline Mutation
por: Choi, Young Sik, et al.
Publicado: (2013)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Somatic Mutations in the RET Protooncogene in Japanese and Chinese Sporadic Medullary Thyroid Carcinomas
por: Shan, Liang, et al.
Publicado: (1998)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
por: Lu, Shun, et al.
Publicado: (2023)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
por: Bardet, Stéphane, et al.
Publicado: (2022)

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

Novel Point Mutations and Allele Loss at the RET Locus in Sporadic Medullary Thyroid Carcinomas
por: Uchino, Shinya, et al.
Publicado: (1998)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
por: Bim, Larissa V., et al.
Publicado: (2019)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Thyroid: Medullary Carcinoma
por: Somnay, Yash R., et al.
Publicado: (2013)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

Large‐scale Analysis of Mutations in RET Exon 16 in Sporadic Medullary Thyroid Carcinomas in Japan
por: Takano, Torn, et al.
Publicado: (2001)

Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity
por: Alqahtani, Tariq, et al.
Publicado: (2021)

Metastatic medullary thyroid carcinoma: A case report
por: Niafar, Mitra, et al.
Publicado: (2011)

Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast
por: Kanteti, Archana P., et al.
Publicado: (2020)

Medullary thyroid carcinoma (MTC): unusual metastatic sites
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance
por: Innella, Giovanni, et al.
Publicado: (2020)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
por: Ahn, Hwa Young, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6uh1lil2u6id85prnjmmc11do1